Peregrine Pharma Stock Crater on Lung Cancer Drug Blowup TheStreet.com But Peregrine conducted half the study in India and Eastern Europe -- geographies with bad reputations for producing overly positive results that cannot be reproduced in larger, confirmatory clinical trials. The median overall survival of 5.6 months in ... |
